pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab,Cisplatin,Vinorelbine,Gemcitabine,Docetaxel,Pemetrexed,Carboplatin,Paclitaxel
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
[]
amazing talk by cross trials comparisons of peri-op io. neoadj seems advantageous. the remains,what to do with poor path responders? frequent discussion at our tb, data is badly needed. didn t bring up radiation as an option for persistent n2. thoughts? 
Thoracic, Trauma & Foregut Surgery @CIUSSSNMTL & @McGillU, Chief of Thoracic @ Sacré-Coeur Hospit, Assist Professor @UMontreal, Alum @Stanford